Home › Research › Brain tissue and pathology
The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer's Disease
Hanslik KL, Ulland TK.. Frontiers in neurology, 2020-09-18
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) is the most prevalent form of late-onset dementia. AD affects the health of millions of people in the United States and worldwide. Currently, there are no approved therapies that can halt or reverse the clinical progression of AD.
What this study adds
Evidence grade: Low
This is a narrative review. This paper notes that there are currently no approved therapies that can halt or reverse the clinical progression of Alzheimer's disease and discusses the role of microglia and the Nlrp3 inflammasome. It reports no treatment, cure or prevention for the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hanslik, K. L., & Ulland, T. K. (2020). The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer's Disease. Frontiers in neurology. https://doi.org/10.3389/fneur.2020.570711
Vancouver
Hanslik KL, Ulland TK. The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer's Disease. Frontiers in neurology. 2020. doi:10.3389/fneur.2020.570711. PMID: 33071950.
BibTeX
@article{hanslik2020-33071950,
author = {Hanslik, K. L. and Ulland, T. K.},
title = {{The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer's Disease}},
journal = {Frontiers in neurology},
year = {2020},
doi = {10.3389/fneur.2020.570711},
pmid = {33071950},
url = {https://doi.org/10.3389/fneur.2020.570711}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- AD affects the health of millions of people in the United States and worldwide.
- Currently, there are no approved therapies that can halt or reverse the clinical progression of AD.
- Traditionally, AD is characterized first by the appearance of amyloid-β (Aβ) plaques followed by the formation of intraneuronal neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau (p-tau).
- These lesions are linked to synapse loss and eventual cognitive impairment.
Why it matters
This paper notes that there are currently no approved therapies that can halt or reverse the clinical progression of Alzheimer's disease and discusses the role of microglia and the Nlrp3 inflammasome. It reports no treatment, cure or prevention for the disease.
Study details
- Evidence strengthLow
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in neurology) |
| Journal's citation record | 2 / 4 | Frontiers in Neurology: journal h-index 162 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 235 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 29.4 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 4 / 6 | Cited 9.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 3 / 4 | Cited 123 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Tyler Kent Ulland: h-index 31 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Wisconsin–Madison: institution h-index 1,518 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33071950) |
| Free to read | 2 / 2 | Free to read |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fneur.2020.570711
- PubMed: 33071950
- Original source →
- Free full text: Frontiers in Neurology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Brain tissue and pathology from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.